ClinicalTrials.gg
CompletedNCT03458325FREEDOM-HFUpdated Feb 24, 2023Results posted

Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure

A Phase 3 interventional study of Furoscix Infusor in Heart Failure, sponsored by scPharmaceuticals, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-24.

Sponsored by scPharmaceuticals, Inc. (part of Mannkind Corporation) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,157 studies in Heart Failure with a site in United States — 347 open to participants now, 437 under way, 27 of them phase 3. Heart Failure · United States.

Enrollment
1,130th of 1,601
27 · median 65
Started
2020
with 97 others
Phase 3
147 of 2,157
21 open now
Registered
1,246th of 2,157
by date

Among the 2,157 studies in Heart Failure with a site in United States, this one is the 1,130th largest by enrollment of the 1,601 interventional ones that give a count, is one of 98 that started in 2020, is one of 147 in phase 3, and was the 1,246th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

347 of the 2,157 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

342 more — sign in →

All 347 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,157 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

The study is to evaluate the safe admission avoidance and the overall economic impact associated with management of worsening HF using the drug-device combination product, the Furoscix Infusor, outside the hospital setting in patients initially presenting to the emergency department.

The study drug, Furoscix (furosemide injection 8 mg/ml), is a furosemide solution buffered to a neutral pH containing 80 mg/10 mL for subcutaneous administration over 5 hours via the Furoscix Infusor.

The study objectives are:

  1. To evaluate differences in healthcare resource utilization and direct medical costs for patients treated with the Furoscix Infusor outside the hospital versus patients receiving intravenous furosemide for ≤ 72 hours in the hospital setting for 30 days post-discharge from the emergency department.
  2. To evaluate the safety of Furoscix administered outside the hospital.
  3. To evaluate and describe quality of life and patient satisfaction for patients who receive the Furoscix Infusor outside the hospital setting.
Read the detailed description

This adaptive clinical trial will include a prospective treatment arm (i.e., Furoscix administered via the Furoscix Infusor) administered outside the hospital that will be compared to a propensity-matched historical control arm of patients admitted to the hospital for ≤ 72 hours (i.e., Treatment As Usual (TAU)) that will be derived from administrative claims data. Eligible patients for the Furoscix arm will be patients with HF and fluid overload who initially present to the emergency department (ED) and who are expected to require parenteral diuresis.

If it is determined by the investigator that the patient requires parenteral diuresis or continued diuresis outside of the ED care setting and meets all study eligibility criteria, he/she may be consented and enrolled into the study.

The treatment comprises a preprogrammed bi-phasic 5-hour drug administration. Subjects will be instructed on the use of the Furoscix Infusor by the investigator and/or study staff in accordance with the instructions for use. The initial dose of the study product may be administered in the ED or at home. Additional doses will be provided to the subject for self-administration or administration by a caregiver in the home setting as directed by the investigator or study staff. The total duration in days and total number of doses of the initial therapy will be determined by the investigator based on an estimated volume of diuresis desired to transition patient back to their oral diuretic maintenance therapy. Subjects will receive scheduled at-home telephone calls from a HF nurse on Days 1 and 7 and one call between Days 14-21. Planned in-clinic visits will be conducted between Day 2-4 and then Day 30. Unscheduled at-home telephone calls by a HF nurse and unscheduled in-clinic visits may be performed if felt clinically indicated by the study team or the clinical provider.

The study period will be up to 30 days after enrollment. All outcomes will be assessed up to 30 days after the initial discharge from the emergency department.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years
  2. Class II-III HF presenting to the emergency department for worsening HF at baseline
  3. On background therapy includes those receiving 40-160 mg of oral furosemide equivalents daily (20-80 mg Torsemide or 1-4 mg Bumetanide).
  4. Signs of extracellular volume expansion, defined as one or more of the following:

    1. jugular venous distention
    2. pitting edema (≥1+),
    3. abdominal distension
    4. pulmonary congestion on chest x-ray
    5. pulmonary rales
  5. After initial emergency department evaluation and treatment (i.e., at the time of the care transition decision*), candidates for parenteral diuresis outside of the hospital, defined as all the following:

    1. Oxygen saturation ≥ 90% on exertion
    2. Respiratory Rate \< 24 breaths per minute
    3. Resting Heart Rate \< 100 beats per minute
    4. Systolic Blood Pressure > 100 mmHg
  6. Adequate environment for at-home administration of Furoscix

Exclusion criteria

Exclusion Criteria:

  1. Presence of a complicating condition, other than HF that requires immediate hospitalization or anticipated hospitalization in the next 30 days
  2. Evidence of acute renal failure as determined at the discretion of the investigator
  3. Known allergy to the active and inactive ingredients of the study medication or device adhesive
  4. Any local abdominal skin condition on the day of treatment i.e. sunburn, rash, eczema, etc.
  5. Currently participating in another interventional research study
  6. Women who are pregnant or who could become pregnant and are not willing to use an adequate form of
  7. Estimated \< 30 mL per minute by Cockcroft-Gault equation

    CrCl (mL/min) = {(140 - age) x Lean Body Weight (kg)/Serum Creatinine (mg/dL) x 72} (x 0.85 if female)

  8. If baseline creatinine value is available: an increase of ≥ 0.5 mg/dL in creatinine from baseline
  9. HF requiring immediate hospitalization
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Furoscix Infusor Prospective Treatment

    Furoscix (furosemide injection, 8 mg/mL) administered subcutaneously over 5 hours via the Furoscix Infusor outside the hospital.

    Combination Product: Furoscix Infusor

  • No intervention
    Propensity-Matched Historical Control

    The control arm will be populated with claims data for patients with HF and fluid overload who presented to the emergency department and were admitted to the hospital for ≤ 72 hours for the treatment of HF with intravenous diuretics. Patients admitted for diuresis-only will be identified by using diagnostic codes for admittance from a claims database.

Interventions

  • Combination productFuroscix Infusor

    Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.

06

What researchers measure

Primary outcomes

  1. Healthcare Utilization Costs

    The difference in the overall and heart failure related healthcare costs between subjects treated with the Furoscix Infusor through 30 days post discharge from the emergency department compared to matched controls treated in the hospital for ≤ 72 hours through 30 days post discharge.

    Time frame: Day 0 - Day 30

Secondary outcomes

  1. Heart-Failure Related Hospital Admissions

    The HF-related admissions for the Furoscix patients compared to Control patients.

    Time frame: Day 0 - Day 30

  2. All-Cause Hospital Admissions

    The differences in the percentage of subjects with an all-cause hospitalization in the Furoscix group and all-cause 30-day rehospitalization in the Control group in the 30 day follow-up period

    Time frame: Day 0 - Day 30

  3. Heart-Failure Related Emergency Department Visits

    The differences in the percentage of patients with HF-related emergency department visits in the Furoscix group and in the Control group in the 30 day follow-up period

    Time frame: Day 0 - Day 30

  4. Heart-Failure Related Clinic Visits

    The differences in the percentage of patients with HF-related clinic visits in the Furoscix group and in the Control group in the 30 day follow-up period

    Time frame: Day 0 - Day 30

  5. KCCQ-12 Scores

    The Kansas City Cardiomyopathy Questionnaire (KCCQ) measures a patient's self-reported overall health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life (QOL). The KCCQ-12 overall summary score is the sum of responses from all 12 items ranging from 0 to 100 with higher scores to indicate better health status.

    Time frame: 30 Days

  6. Mean Change in NT-proBNP and BNP

    Change in NT-proBNP and BNP change from baseline during the study period is summarized for the Furoscix group

    Time frame: Day 0 - Day 30

  7. Comfort of Wear Questionnaire

    The Furoscix group was administered a Comfort of Wear Questionnaire during Day 2-4 study visit. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.

    Time frame: Day 0 - Day 2-4 study visit

  8. Comfort of Wear Questionnaire: Interference With Activities Daily Living

    The Furoscix group was administered a Comfort of Wear Questionnaire on Day 2-4. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.

    Time frame: Day 0 - Day 2-4 study visit

  9. Comfort of Wear Questionnaire: Subject and/or Caregiver Satisfaction

    The Furoscix group was administered a Comfort of Wear Questionnaire during Day 2-4 study visit. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.

    Time frame: Day 0 - Day 2-4 study visit

07

Results

Posted Feb 24, 2023

Participant flow

Participant flow — Overall Study
MilestoneFuroscix Infusor Prospective Treatment
Started25
Completed24
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryHealthcare Utilization Costs

The difference in the overall and heart failure related healthcare costs between subjects treated with the Furoscix Infusor through 30 days post discharge from the emergency department compared to matched controls treated in the hospital for ≤ 72 hours through 30 days post discharge.

Time frame:
Day 0 - Day 30
Reported as:
Mean · US Dollars
Healthcare Utilization Costs
US DollarsFuroscix Infusor Prospective Treatment
HF-related healthcare costs2920.30 ± 7073.20
Overall healthcare costs7512.30 ± 11,905.50
Statistical analysis
  • Furoscix Infusor Prospective Treatment · t-test, 2 sided · p = <0.0001 · Mean difference (final values): -16,995.30 · 95% CI -22,187.90 to -11,802.70
SecondaryHeart-Failure Related Hospital Admissions

The HF-related admissions for the Furoscix patients compared to Control patients.

Time frame:
Day 0 - Day 30
Reported as:
Count of participants · Participants
Heart-Failure Related Hospital Admissions
ParticipantsFuroscix Infusor Prospective Treatment
Heart-Failure Related Hospital Admissions1
Statistical analysis
  • Furoscix Infusor Prospective Treatment · Fisher Exact · p = 0.6765 · Percentage difference: -6.4
SecondaryAll-Cause Hospital Admissions

The differences in the percentage of subjects with an all-cause hospitalization in the Furoscix group and all-cause 30-day rehospitalization in the Control group in the 30 day follow-up period

Time frame:
Day 0 - Day 30
Reported as:
Count of participants · Participants
All-Cause Hospital Admissions
ParticipantsFuroscix Infusor Prospective Treatment
All-Cause Hospital Admissions6
Statistical analysis
  • Furoscix Infusor Prospective Treatment · Fisher Exact · p = 0.5856 · Mean difference (net): 5.3
SecondaryHeart-Failure Related Emergency Department Visits

The differences in the percentage of patients with HF-related emergency department visits in the Furoscix group and in the Control group in the 30 day follow-up period

Time frame:
Day 0 - Day 30
Reported as:
Count of participants · Participants
Heart-Failure Related Emergency Department Visits
ParticipantsFuroscix Infusor Prospective TreatmentMatched Historical Control
Heart-Failure Related Emergency Department Visits14
Statistical analysis
  • Furoscix Infusor Prospective Treatment vs Matched Historical Control · Fisher Exact · p = 1.000 · Mean difference (net): -1.9
SecondaryHeart-Failure Related Clinic Visits

The differences in the percentage of patients with HF-related clinic visits in the Furoscix group and in the Control group in the 30 day follow-up period

Time frame:
Day 0 - Day 30
Reported as:
Count of participants · Participants
Heart-Failure Related Clinic Visits
ParticipantsFuroscix Infusor Prospective Treatment
Heart-Failure Related Clinic Visits24
Statistical analysis
  • Furoscix Infusor Prospective Treatment · Chi-squared · p = <0.0001 · Mean difference (net): 65.1
SecondaryKCCQ-12 Scores

The Kansas City Cardiomyopathy Questionnaire (KCCQ) measures a patient's self-reported overall health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life (QOL). The KCCQ-12 overall summary score is the sum of responses from all 12 items ranging from 0 to 100 with higher scores to indicate better health status.

Time frame:
30 Days
Reported as:
Mean · score on a scale
KCCQ-12 Scores
score on a scaleFuroscix Infusor Prospective Treatment - BaselineFuroscix Infusor Prospective Treatment - Day 30
Summary Score29.9 ± 22.842.8 ± 28.4
Physical Limitation Score37.1 ± 30.143.7 ± 32.0
Symptom Frequency Score33.1 ± 28.650.5 ± 32.3
Quality of Life Score27.1 ± 28.035.9 ± 29.8
Social Limitation Score29.0 ± 26.140.9 ± 31.3
Statistical analysis
  • Furoscix Infusor Prospective Treatment - Baseline vs Furoscix Infusor Prospective Treatment - Day 30 · t-test, 2 sided · p = 0.0443 · Mean difference (net): 12.8 · 95% CI 0.4 to 25.3P-value was obtained from the paired t-test statistic.
SecondaryMean Change in NT-proBNP and BNP

Change in NT-proBNP and BNP change from baseline during the study period is summarized for the Furoscix group

Time frame:
Day 0 - Day 30
Reported as:
Mean · pg/ml
Mean Change in NT-proBNP and BNP
pg/mlFuroscix Infusor Prospective Treatment - BaselineFuroscix Infusor Prospective Treatment - Day 30
NT-proBNP823.4 ± 1043.9700.7 ± 896.2
BNP785.1 ± 1129.9263.5 ± 384.0
Statistical analysis
  • Furoscix Infusor Prospective Treatment - Baseline vs Furoscix Infusor Prospective Treatment - Day 30 · t-test, 2 sided · p = 0.5133 · Mean difference (final values): -122.6 · 95% CI -525.8 to 280.5
  • Furoscix Infusor Prospective Treatment - Baseline vs Furoscix Infusor Prospective Treatment - Day 30 · t-test, 2 sided · p = 0.0420 · Mean difference (final values): -719.9 · 95% CI -1406.5 to -33.2
SecondaryComfort of Wear Questionnaire

The Furoscix group was administered a Comfort of Wear Questionnaire during Day 2-4 study visit. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.

Time frame:
Day 0 - Day 2-4 study visit
Reported as:
Count of participants · Participants
Comfort of Wear Questionnaire
ParticipantsFuroscix Infusor Prospective Treatment
Please rate how comfortable or uncomfortable you felt wearing the device — Very Comfortable6
Please rate how comfortable or uncomfortable you felt wearing the device — Moderately Comfortable9
Please rate how comfortable or uncomfortable you felt wearing the device — Slightly Comfortable3
Please rate how comfortable or uncomfortable you felt wearing the device — Neither Comfortable or Uncomfortable0
Please rate how comfortable or uncomfortable you felt wearing the device — Slightly Uncomfortable5
Please rate how comfortable or uncomfortable you felt wearing the device — Moderately Uncomfortable1
Please rate how comfortable or uncomfortable you felt wearing the device — Very Uncomfortable0
Please rate how comfortable or uncomfortable you felt upon removal of the device — Very Comfortable11
Please rate how comfortable or uncomfortable you felt upon removal of the device — Moderately Comfortable4
Please rate how comfortable or uncomfortable you felt upon removal of the device — Slightly Comfortable2
Please rate how comfortable or uncomfortable you felt upon removal of the device — Neither Comfortable or Uncomfortable4
Please rate how comfortable or uncomfortable you felt upon removal of the device — Slightly Uncomfortable1
Please rate how comfortable or uncomfortable you felt upon removal of the device — Moderately Uncomfortable1
Please rate how comfortable or uncomfortable you felt upon removal of the device — Very Uncomfortable1
SecondaryComfort of Wear Questionnaire: Interference With Activities Daily Living

The Furoscix group was administered a Comfort of Wear Questionnaire on Day 2-4. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.

Time frame:
Day 0 - Day 2-4 study visit
Reported as:
Count of participants · Participants
Comfort of Wear Questionnaire: Interference With Activities Daily Living
ParticipantsFuroscix Infusor Prospective Treatment
If wearing the device interfered with activities of daily living - Walking — 1 - Not at all19
If wearing the device interfered with activities of daily living - Walking — 2 - Probably Not1
If wearing the device interfered with activities of daily living - Walking — 3 - Possibly1
If wearing the device interfered with activities of daily living - Walking — 4 - Probably1
If wearing the device interfered with activities of daily living - Walking — 5 - Completely1
If wearing the device interfered with activities of daily living - Walking — Not Applicable1
If wearing the device interfered with activities of daily living - Standing — 1 - Not at all19
If wearing the device interfered with activities of daily living - Standing — 2 - Probably Not1
If wearing the device interfered with activities of daily living - Standing — 3 - Possibly1
If wearing the device interfered with activities of daily living - Standing — 4 - Probably1
If wearing the device interfered with activities of daily living - Standing — 5 - Completely1
If wearing the device interfered with activities of daily living - Standing — Not Applicable1
If wearing the device interfered with activities of daily living - Sitting reading watching TV — 1 - Not at all17
If wearing the device interfered with activities of daily living - Sitting reading watching TV — 2 - Probably Not5
If wearing the device interfered with activities of daily living - Sitting reading watching TV — 3 - Possibly0
If wearing the device interfered with activities of daily living - Sitting reading watching TV — 4 - Probably0
If wearing the device interfered with activities of daily living - Sitting reading watching TV — 5 - Completely1
If wearing the device interfered with activities of daily living - Sitting reading watching TV — Not Applicable1
If wearing the device interfered with activities of daily living - Lying down/napping — 1 - Not at all13
If wearing the device interfered with activities of daily living - Lying down/napping — 2 - Probably Not4
If wearing the device interfered with activities of daily living - Lying down/napping — 3 - Possibly2
If wearing the device interfered with activities of daily living - Lying down/napping — 4 - Probably2
If wearing the device interfered with activities of daily living - Lying down/napping — 5 - Completely0
If wearing the device interfered with activities of daily living - Lying down/napping — Not Applicable3
If wearing the device interfered with activities of daily living - Using the bathroom — 1 - Not at all17
If wearing the device interfered with activities of daily living - Using the bathroom — 2 - Probably Not2
If wearing the device interfered with activities of daily living - Using the bathroom — 3 - Possibly1
If wearing the device interfered with activities of daily living - Using the bathroom — 4 - Probably3
If wearing the device interfered with activities of daily living - Using the bathroom — 5 - Completely1
If wearing the device interfered with activities of daily living - Using the bathroom — Not Applicable0
If wearing the device interfered with activities of daily living - Driving or riding in a car — 1 - Not at all14
If wearing the device interfered with activities of daily living - Driving or riding in a car — 2 - Probably Not4
If wearing the device interfered with activities of daily living - Driving or riding in a car — 3 - Possibly1
If wearing the device interfered with activities of daily living - Driving or riding in a car — 4 - Probably0
If wearing the device interfered with activities of daily living - Driving or riding in a car — 5 - Completely0
If wearing the device interfered with activities of daily living - Driving or riding in a car — Not Applicable5
SecondaryComfort of Wear Questionnaire: Subject and/or Caregiver Satisfaction

The Furoscix group was administered a Comfort of Wear Questionnaire during Day 2-4 study visit. This questionnaire measured the patient's general perception of comfortability wearing and using the device, the impact of wearing the device on their activities of daily living, and their satisfaction with the device.

Time frame:
Day 0 - Day 2-4 study visit
Reported as:
Count of participants · Participants
Comfort of Wear Questionnaire: Subject and/or Caregiver Satisfaction
ParticipantsFuroscix Infusor Prospective Treatment
I think that I would like to use this product frequently — 1 - Strongly Disagree0
I think that I would like to use this product frequently — 2 - Disagree2
I think that I would like to use this product frequently — 3 - Neutral7
I think that I would like to use this product frequently — 4 - Agree2
I think that I would like to use this product frequently — 5 - Strongly Agree13
I found the product unnecessarily complex — 1 - Strongly Disagree14
I found the product unnecessarily complex — 2 - Disagree7
I found the product unnecessarily complex — 3 - Neutral0
I found the product unnecessarily complex — 4 - Agree1
I found the product unnecessarily complex — 5 - Strongly Agree2
I thought the product was easy to use — 1 - Strongly Disagree0
I thought the product was easy to use — 2 - Disagree2
I thought the product was easy to use — 3 - Neutral0
I thought the product was easy to use — 4 - Agree4
I thought the product was easy to use — 5 - Strongly Agree18
I think that I would need the support of a technical person to be able to use this product — 1 - Strongly Disagree22
I think that I would need the support of a technical person to be able to use this product — 2 - Disagree0
I think that I would need the support of a technical person to be able to use this product — 3 - Neutral1
I think that I would need the support of a technical person to be able to use this product — 4 - Agree0
I think that I would need the support of a technical person to be able to use this product — 5 - Strongly Agree1
I found the various functions in this product were well integrated — 1 - Strongly Disagree2
I found the various functions in this product were well integrated — 2 - Disagree2
I found the various functions in this product were well integrated — 3 - Neutral2
I found the various functions in this product were well integrated — 4 - Agree4
I found the various functions in this product were well integrated — 5 - Strongly Agree14
I thought there was too much inconsistency in this product — 1 - Strongly Disagree18
I thought there was too much inconsistency in this product — 2 - Disagree5
I thought there was too much inconsistency in this product — 3 - Neutral1
I thought there was too much inconsistency in this product — 4 - Agree0
I thought there was too much inconsistency in this product — 5 - Strongly Agree0
I would imagine that most people would learn to use this product very quickly — 1 - Strongly Disagree0
I would imagine that most people would learn to use this product very quickly — 2 - Disagree0
I would imagine that most people would learn to use this product very quickly — 3 - Neutral0
I would imagine that most people would learn to use this product very quickly — 4 - Agree1
I would imagine that most people would learn to use this product very quickly — 5 - Strongly Agree23
I found the product very cumbersome to use — 1 - Strongly Disagree11
I found the product very cumbersome to use — 2 - Disagree4
I found the product very cumbersome to use — 3 - Neutral5
I found the product very cumbersome to use — 4 - Agree1
I found the product very cumbersome to use — 5 - Strongly Agree3
I felt very confident using the product — 1 - Strongly Disagree0
I felt very confident using the product — 2 - Disagree0
I felt very confident using the product — 3 - Neutral0
I felt very confident using the product — 4 - Agree5
I felt very confident using the product — 5 - Strongly Agree19
I needed to learn a lot of things before I could get going with this product — 1 - Strongly Disagree15
I needed to learn a lot of things before I could get going with this product — 2 - Disagree3
I needed to learn a lot of things before I could get going with this product — 3 - Neutral2
I needed to learn a lot of things before I could get going with this product — 4 - Agree3
I needed to learn a lot of things before I could get going with this product — 5 - Strongly Agree1

Adverse events

Collected over 30 Days from Enrollment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Furoscix Infusor Prospective Treatment0/24 (0%)6/24 (25%)18/24 (75%)
Most frequent serious events
Most frequent serious events
EventFuroscix Infusor Prospective Treatment
Cardiac Failure CongestiveCardiac disorders1/24
Food PoisoningGastrointestinal disorders1/24
Tibia FractureInjury, poisoning and procedural complications1/24
Diabetic KetoacidosisMetabolism and nutrition disorders1/24
Hyperosmolar StateMetabolism and nutrition disorders1/24
HypovolaemiaMetabolism and nutrition disorders1/24
Acute Kidney InjuryRenal and urinary disorders1/24
PolyuriaRenal and urinary disorders1/24
LymphedemaVascular disorders1/24
Most frequent other events
Most frequent other events
EventFuroscix Infusor Prospective Treatment
Infusion Site BruisingGeneral disorders7/24
Infusion Site PainGeneral disorders7/24
DizzinessNervous system disorders3/24
Infusion Site HemorrhageGeneral disorders2/24
Muscle SpasmsMusculoskeletal and connective tissue disorders2/24
Urinary Tract InfectionInfections and infestations2/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)Furoscix Infusor Prospective Treatment
Mean56.3 ± 12.29
Sex: Female, Male
Sex: Female, Male(Participants)Furoscix Infusor Prospective Treatment
Female9
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Furoscix Infusor Prospective Treatment
Hispanic or Latino0
Not Hispanic or Latino24
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Furoscix Infusor Prospective Treatment
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American10
White12
More than one race0
Unknown or Not Reported0
Subject's Insurance at baseline
Subject's Insurance at baseline(Participants)Furoscix Infusor Prospective Treatment
Medicare8
Medicaid4
Commercial10
Unknown2
NYHA Classification
NYHA Classification(Participants)Furoscix Infusor Prospective Treatment
NYHA Class I0
NYHA Class II4
NYHA Class III20
NYHA Class IV0
Signs of volume expansion at baseline
Signs of volume expansion at baseline(Participants)Furoscix Infusor Prospective Treatment
Jugular Venous Distention4
Pitting Edema18
Abdominal Distention9
Pulmonary Congestion on Chest X-ray6
Pulmonary Rales5
History of Congestive Heart Failure (CHF)
History of Congestive Heart Failure (CHF)(Years)Furoscix Infusor Prospective Treatment
Mean4.26 ± 4.917

1 further baseline measures are reported on the registry.

08

Study locations

8 sites
  • Olive View - UCLA Medical Center
    Sylmar, California 91342, United States
  • Bridgeport Hospital
    Bridgeport, Connecticut 06610, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • Ascension St. Vincent Heart Center
    Indianapolis, Indiana 46260, United States
  • Unity Point Health
    Des Moines, Iowa 50309, United States
  • University of Minnesota Medical Center
    Minneapolis, Minnesota 55422, United States
  • Moses H. Cone Memorial Hospital
    Greensboro, North Carolina 27401, United States
  • Abington Hospital - Jefferson Health
    Abington, Pennsylvania 19001, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jun 2021, 7 months.

Results were first posted in Feb 2023, 1 year 8 months after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 7 months is below that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2018
First posted
Mar 8, 2018
StartActual
Nov 12, 2020
Primary completionActual
Jun 24, 2021
CompletionActual
Jun 24, 2021
Results first posted
Feb 24, 2023
Last update
Feb 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03458325
Responsible party
Sponsor
First posted
Mar 8, 2018
Start date
Nov 12, 2020
Primary completion
Jun 24, 2021
Completion
Jun 24, 2021
Results posted
Feb 24, 2023
Last update
Feb 24, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion